Sotac Pharmaceuticals (NSE:SOTAC) Short-Term Debt: ₹272.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
49 GF Score
Price ₹91.95
GF Value ₹141.87
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals Short-Term Debt?

Sotac Pharmaceuticals NSE:SOTAC 49 Short-Term Debt is ₹272.1 Mil as of Mar. 2026. GuruFocus rates NSE:SOTAC with a GF Score™ of 49/100 and a GF Value™ of ₹141.87 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Sotac Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was ₹272.1 Mil.

Sotac Pharmaceuticals's quarterly Short-Term Debt declined from Mar. 2025 (₹295.1 Mil) to Sep. 2025 (₹288.3 Mil) and declined from Sep. 2025 (₹288.3 Mil) to Mar. 2026 (₹272.1 Mil).

Sotac Pharmaceuticals's annual Short-Term Debt increased from Mar. 2024 (₹127.3 Mil) to Mar. 2025 (₹295.1 Mil) but then declined from Mar. 2025 (₹295.1 Mil) to Mar. 2026 (₹272.1 Mil).

Sotac Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sotac Pharmaceuticals Short-Term Debt Related Terms

Sotac Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals Short-Term Debt Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial 64.17 142.70 127.28 295.05 272.09

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 127.28 165.83 295.05 288.34 272.09
NSE:SOTAC
49GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹272.1 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Short-Term Debt of ₹272.1 Mil as of Mar. 2026.
Is Sotac Pharmaceuticals' Short-Term Debt too high?
Sotac Pharmaceuticals' current Short-Term Debt is ₹272.1 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Short-Term Debt compare to ZTS?
Sotac Pharmaceuticals' Short-Term Debt of ₹272.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Sotac Pharmaceuticals's current Short-Term Debt is ₹272.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹141.87, compared to a current price of ₹91.95 — trading 35.2% below its estimated fair value. The current Short-Term Debt is ₹272.1 Mil. Sotac Pharmaceuticals' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Short-Term Debt is ₹272.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹91.95 is trading 35.2% below its estimated GF Value™ of ₹141.87. GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:SOTAC:

  • Short-Term Debt: ₹272.1 Mil
  • GF Value™: ₹141.87 vs. price of ₹91.95 (35.2% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
49GF Score

Get the complete analysis for NSE:SOTAC

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹91.95
Price
₹141.87
GF Value